Cart
sales@molnova.com
Flomoxef sodium
CAS No. 92823-03-5
Flomoxef sodium ( —— )
Catalog No. M26216 CAS No. 92823-03-5
Flomoxef sodium is an oxacyclovir antibiotic with good antibacterial activity against a variety of gram-positive bacteria.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 42 | Get Quote |
|
| 10MG | 68 | Get Quote |
|
| 25MG | 155 | Get Quote |
|
| 50MG | 259 | Get Quote |
|
| 100MG | 357 | Get Quote |
|
| 200MG | 537 | Get Quote |
|
| 500MG | 858 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFlomoxef sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionFlomoxef sodium is an oxacyclovir antibiotic with good antibacterial activity against a variety of gram-positive bacteria.
-
DescriptionFlomoxef sodium is an oxacyclovir antibiotic with good antibacterial activity against a variety of gram-positive bacteria.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number92823-03-5
-
Formula Weight518.4
-
Molecular FormulaC15H17F2N6NaO7S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@]12OCC(CSc3nnnn3CCO)=C(N1C(=O)[C@]2(NC(=O)CSC(F)F)OC)C(=O)O[Na]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Szebenyi SA, Ogura T, Sathyanesan A, AlMatrouk AK, Chang J, Lin W. Increases in intracellular calcium via activation of potentially multiple phospholipase C isozymes in mouse olfactory neurons. Front Cell Neurosci. 2014 Oct 21;8:336.
molnova catalog
related products
-
1,3,3,5,5-pentamethy...
1,3,3,5,5-pentamethylcyclohexan-1-amine hydrochloride is a chemical compound.
-
NIC3
NIC3 is a selective nucleus accumbens-associated protein-1 (NAC1) inhibitor, with anti-cancer activity.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
